Clinical Trials
20 trialsNCT03798626 2026-04-01
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
NCT03013218 2025-08-01
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
Phase 1 Completed
NCT02791334 2024-09-27
PACT
Eli Lilly and Company
Phase 1 Completed
NCT02443324 2024-07-31
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02789345 2024-02-05
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
Eli Lilly and Company
Phase 1 Completed
NCT05800418 2023-04-05
Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT02564198 2021-08-17
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT02572687 2021-01-20
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Eli Lilly and Company
Phase 1 Completed
NCT02079636 2020-09-11
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 1 Completed
NCT02745769 2019-03-05
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Eli Lilly and Company
Phase 1 Completed
NCT02069041 2018-11-21
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01285037 2018-02-20
A Study of LY2801653 in Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02359058 2018-01-24
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01682135 2016-08-26
A Study in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT01286818 2014-10-06
A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
Eli Lilly and Company
Phase 1 Completed
NCT01005355 2014-06-18
Study of IMC-1121B in Patients With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT01253525 2014-06-18
Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas
Eli Lilly and Company
Phase 1 Completed
NCT01256567 2014-06-18
A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00786383 2013-08-19
Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy
Eli Lilly and Company
Phase 1 Completed
NCT00793975 2013-08-19
Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy
Eli Lilly and Company
Phase 1 Completed